HEPION PHARMACEUTICALS, INC. Employee-related Liabilities, Current
HEPION PHARMACEUTICALS, INC. (HEPA) had Employee-related Liabilities, Current of $138.39 thousand as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:EmployeeRelatedLiabilitiesCurrent · last filed 2026-08-13
- 2026-06-30: Employee-related Liabilities, Current $138.39K.
- 2026-03-31: Employee-related Liabilities, Current $259.92K.
- 2025-12-31: Employee-related Liabilities, Current $29.17K.
- 2023-12-31: Employee-related Liabilities, Current $0.00.
| Period end | Employee-related Liabilities, Current |
|---|---|
| 2026-06-30 | $138.39K 10-Q · filed 2026-08-13 |
| 2026-03-31 | $259.92K 10-Q · filed 2026-05-14 |
| 2025-12-31 | $29.17K 10-Q · filed 2026-08-13 |
| 2023-12-31 | $0.00 10-K · filed 2024-04-16 |
| 2023-09-30 | $945.03K 10-Q · filed 2023-11-20 |
| 2023-06-30 | $724.10K 10-Q · filed 2023-08-14 |
| 2023-03-31 | $360.61K 10-Q · filed 2023-05-12 |
| 2022-12-31 | $838.68K 10-K · filed 2024-04-16 |
| 2022-09-30 | $852.00K 10-Q · filed 2022-11-14 |
| 2022-06-30 | $515.65K 10-Q · filed 2022-08-15 |
| 2022-03-31 | $222.00K 10-Q · filed 2022-05-16 |
| 2021-12-31 | $0.00 10-K · filed 2023-04-10 |
| 2021-09-30 | $779.24K 10-Q · filed 2021-11-15 |
| 2021-06-30 | $558.24K 10-Q · filed 2021-08-16 |
| 2021-03-31 | $306.49K 10-Q · filed 2021-05-14 |
| 2020-12-31 | $150.70K 10-K · filed 2022-04-08 |
| 2020-09-30 | $540.51K 10-Q · filed 2020-11-16 |
| 2020-06-30 | $381.52K 10-Q · filed 2020-08-12 |
| 2020-03-31 | $190.60K 10-Q · filed 2020-06-29 |
| 2019-12-31 | $346.24K 10-K · filed 2021-03-31 |
| 2019-09-30 | $306.60K 10-Q · filed 2019-11-14 |
| 2019-06-30 | $335.91K 10-Q · filed 2019-08-14 |
| 2019-03-31 | $322.19K 10-Q · filed 2019-05-15 |
| 2018-12-31 | $280.24K 10-K · filed 2020-05-14 |
| 2018-09-30 | $187.68K 10-Q · filed 2018-11-14 |
| 2018-06-30 | $240.17K 10-Q · filed 2018-08-14 |
| 2018-03-31 | $308.98K 10-Q · filed 2018-05-15 |
| 2017-12-31 | $539.06K 10-K · filed 2019-03-14 |
| 2017-09-30 | $975.43K 10-Q · filed 2017-11-14 |
| 2017-06-30 | $931.66K 10-KT · filed 2018-03-26 |
| 2017-03-31 | $716.89K 10-Q · filed 2017-04-12 |
| 2016-12-31 | $490.75K 10-Q · filed 2017-02-14 |
| 2016-09-30 | $277.10K 10-Q · filed 2016-11-14 |
| 2016-06-30 | $489.82K 10-KT · filed 2018-03-26 |
| 2015-06-30 | $94.89K 10-K · filed 2016-09-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |